What we know so far
Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint WSJ The Heart Drug Pelacarsen Fails, Shocking Novartis and Cardiologists nytimes.com NVS, IONS, AMGN Stocks Drop After-Hours — What’s Driving The Selloff? Yahoo Finance Novartis Says Closely Watched Cholesterol Study Failed to Meet Goal WSJ Novartis, Ionis' experimental heart drug misses key goal in closely watched trial Reuters Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint WSJ The Heart Drug Pelacarsen Fails, Shocking Novartis and Cardiologists nytimes.com NVS, IONS, AMGN Stocks Drop After-Hours — What’s Driving The Selloff? Yahoo Finance Novartis Says Closely Watched Cholesterol Study Failed to Meet Goal WSJ Novartis, Ionis' experimental heart drug misses key goal in closely watched trial Reuters
Why this story matters
This business story is being watched because it can affect readers, markets, or public policy in the hours after it breaks. WSJ was among the first outlets to surface the report. YuToday writes an original briefing around the confirmed facts instead of reprinting another outlet’s article.
The latest reporting
Reported context includes the following: Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint WSJ The Heart Drug Pelacarsen Fails, Shocking Novartis and Cardiologists nytimes.com NVS, IONS, AMGN Stocks Drop After-Hours — What’s Driving The Selloff? Yahoo Finance Novartis Says Closely Watched Cholesterol Study Failed to Meet Goal WSJ Novartis, Ionis' experimental heart drug misses key goal in closely watched trial Reuters Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint WSJ The Heart Drug Pelacarsen Fails, Shocking Novartis and Cardiologists nytimes.com NVS, IONS, AMGN Stocks Drop After-Hours — What’s Driving The Selloff? Yahoo Finance Novartis Says Closely Watched Cholesterol Study Failed to Meet Goal WSJ Novartis, Ionis' experimental heart drug misses key goal in closely watched trial Reuters
How YuToday is covering it
The newsroom gathers the confirmed facts, writes a structured briefing with takeaways and common questions, and credits the originating outlet. That keeps the page useful for readers who want the story in one place.
What happens next
Watch for official statements, follow-up data, and confirmation from a second independent outlet. YuToday will refresh this briefing when new facts appear.
